---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-26-000079"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2026-09-08T11:05:26+00:00"
generated_at: "2026-09-08T11:10:16.289258+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Kiora appoints Keith Lane as EVP of Clinical Development and Regulatory Affairs

## Summary
- Lane appointed EVP, Head of Clinical Development and Regulatory Affairs effective Sept 8, 2026.
- Compensation: $350k base salary, $75k sign-on bonus, 35% base target bonus, 55k share option grant.
- Lane brings 20+ yrs ophthalmic experience from Ora; oversaw 60+ trials, incl. 12 global Phase 3 studies.
- Will lead U.S./global clinical development for KIO-301 (retinitis pigmentosa) and other pipeline assets.

## SEC filing metadata
- accession: 0001372514-26-000079
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2026-09-08T11:05:26+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251426000079/0001372514-26-000079-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251426000079/kprx-20260908.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-26-000079
- JSON: https://secwatch.observer/filing/0001372514-26-000079.json
- Plain text: https://secwatch.observer/filing/0001372514-26-000079.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.